Article
The fibroblast growth factor 21 concentration in children with mitochondrial disease does not depend on the disease stage, but rather on the disease genotype.
Pediatric endocrinology, diabetes, and metabolism - 1 Jan 2022
Wesół-Kucharska Dorota, Rokicki Dariusz, Greczan Milena, Kaczor Magdalena, Czekuć-Kryśkiewicz Edyta, Piekutowska-Abramczuk Dorota, Halat-Wolska Paulina, Ciara Elżbieta, Jaworski Maciej, Jezela-Stanek Aleksandra
Abstract excerpt
ABSTRACT: The fibroblast growth factor 21 (FGF21) is a new biomarker of mitochondrial diseases (MD). FGF21 concentration may be used to define the severity of mitochondrial disease. AIM OF THE STUDY: The study objective was to verify if the FGF21 concentration in paediatric patients with MD was correlated with the disease severity and stage and to assess the correlation between FGF21 levels and the genetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.